At Cullinan Oncology, we believe that developing transformational cancer therapies requires collaboration, both in R&D and in clinical development. We work closely with leading academic and corporate research organizations to discover and in-license promising science, and we work closely with clinical development partners to shepherd those assets through the clinic.

Asset Collaborations

The Wistar Institute (Wistar) is a global leader in biomedical research in the areas of cancer, immunology, and infectious disease. Cullinan Apollo, a wholly owned subsidiary of Cullinan Oncology LLC, is developing VK-2019, a novel first-in-class EBNA1 inhibitor discovered at The Wistar Institute. Wistar has granted Cullinan Apollo an exclusive worldwide license for the development and commercialization of VK-2019, which in preclinical models inhibited tumor growth in EBV-associated cancers.
Taiho Pharmaceutical is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Taiho Pharmaceutical has granted an exclusive, global license ex-Japan for the development and commercialization of TAS6417 to Cullinan Pearl, a newly formed US-based company under the Cullinan Oncology umbrella. TAS6147 is a best-in class tyrosine kinase inhibitor designed to target activating mutations in EGFR (Epidermal Growth Factor Receptor) for the treatment of NSCLC (Non-Small Cell Lung Cancer).
The Fred Hutchinson Cancer Research Center (Fred Hutch), home to three Nobel laureates and interdisciplinary teams of world-renowned scientists, seeks new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. Fred Hutch and Cullinan Oncology LLC are collaborating on the development of a first-in-class autologous T Cell therapy for the treatment of HPV-associated cancers and other conditions.

Development Collaborations

ICON is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology medical device, and government and public health organizations. They focus their innovation on the factors that are critical to clients – reducing time to market, reducing cost, and increasing quality – and its global team of experts has extensive experience in a broad range of therapeutic areas.